tiprankstipranks
Trending News
More News >

BioCryst price target raised to $15 from $13 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on BioCryst (BCRX) to $15 from $13 and keeps a Buy rating on the shares after the company announced an agreement to sell the European Orladeyo business to Neopharmed Gentili for up to $264M. The firm is “encouraged” by the deal given the majority of Orladeyo revenues are realized in the U.S. and it provides clear line of sight for settling outstanding debt, the analyst tells investors.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1